ME02102B - Novi polimorf - Google Patents

Novi polimorf

Info

Publication number
ME02102B
ME02102B MEP-2015-56A MEP5615A ME02102B ME 02102 B ME02102 B ME 02102B ME P5615 A MEP5615 A ME P5615A ME 02102 B ME02102 B ME 02102B
Authority
ME
Montenegro
Prior art keywords
solid form
form according
nocturia
vasopressin
solvate
Prior art date
Application number
MEP-2015-56A
Other languages
English (en)
Unknown language (me)
Inventor
Björn Erik Johanson
Johan Henrik Kjellström
Thomas Vilhelmsen
Original Assignee
Vantia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vantia Ltd filed Critical Vantia Ltd
Publication of ME02102B publication Critical patent/ME02102B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
MEP-2015-56A 2010-04-01 2011-03-31 Novi polimorf ME02102B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1005623.2A GB201005623D0 (en) 2010-04-01 2010-04-01 New polymorph
US34704810P 2010-05-21 2010-05-21
EP11714079.8A EP2552910B1 (en) 2010-04-01 2011-03-31 New polymorph
PCT/GB2011/000500 WO2011121308A1 (en) 2010-04-01 2011-03-31 New polymorph

Publications (1)

Publication Number Publication Date
ME02102B true ME02102B (me) 2015-10-20

Family

ID=42228830

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-56A ME02102B (me) 2010-04-01 2011-03-31 Novi polimorf

Country Status (20)

Country Link
US (1) US9079881B2 (enExample)
EP (1) EP2552910B1 (enExample)
JP (1) JP5802737B2 (enExample)
KR (1) KR101792621B1 (enExample)
CN (1) CN102918038B (enExample)
CA (1) CA2795109C (enExample)
DK (1) DK2552910T3 (enExample)
ES (1) ES2538085T3 (enExample)
GB (1) GB201005623D0 (enExample)
HR (1) HRP20150513T1 (enExample)
HU (1) HUE026442T2 (enExample)
ME (1) ME02102B (enExample)
MX (1) MX2012011382A (enExample)
PL (1) PL2552910T3 (enExample)
PT (1) PT2552910E (enExample)
RS (1) RS53956B1 (enExample)
RU (1) RU2559633C2 (enExample)
SI (1) SI2552910T1 (enExample)
SM (1) SMT201500107B (enExample)
WO (1) WO2011121308A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105537D0 (en) * 2011-03-31 2011-05-18 Vantia Ltd New process
CN103755707B (zh) * 2013-09-17 2015-11-18 天津药物研究院 利希普坦晶型ⅱ及其制备方法和用途
CN104059070B (zh) * 2013-09-17 2016-02-10 天津药物研究院有限公司 利希普坦晶型ⅰ及其制备方法和用途
CN103694240B (zh) * 2013-09-18 2015-11-18 天津药物研究院 利希普坦的溶剂合物及其制备方法和用途
CN104140429B (zh) * 2014-07-25 2015-11-18 天津药物研究院 利希普坦晶型ⅴ及其制备方法和用途
CN108026059A (zh) 2015-07-22 2018-05-11 阿纳韦克斯生命科学公司 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型,制备这样晶型的方法,及其药物组合物
WO2020154581A1 (en) 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
BR9811585A (pt) 1997-07-30 2000-09-26 American Home Prod Agonistas de vasopressinas tricìclicas
EP1000059B1 (en) 1997-07-30 2004-09-29 Wyeth Tricyclic vasopressin agonists
CN1347415A (zh) 1999-02-04 2002-05-01 美国家用产品公司 三环吡啶n-氧化物血管升压素激动剂
WO2000046225A2 (en) 1999-02-04 2000-08-10 American Home Products Corporation Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
JP2002536378A (ja) 1999-02-04 2002-10-29 ワイス ピロロベンゾジアゼピンカルボキシアミドバソプレシンアゴニスト
CN1339036A (zh) 1999-02-04 2002-03-06 美国家用产品公司 作为血管加压素激动剂的噻吩基苯甲酰基苯并吖庚因
GB0000079D0 (en) * 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
GB0015601D0 (en) * 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents

Also Published As

Publication number Publication date
EP2552910A1 (en) 2013-02-06
US20140296213A1 (en) 2014-10-02
SI2552910T1 (sl) 2015-06-30
SMT201500107B (it) 2015-07-09
KR20130023218A (ko) 2013-03-07
CA2795109C (en) 2018-04-17
HRP20150513T1 (hr) 2015-06-05
CA2795109A1 (en) 2011-10-06
RS53956B1 (sr) 2015-08-31
RU2012146544A (ru) 2014-05-10
RU2559633C2 (ru) 2015-08-10
KR101792621B1 (ko) 2017-11-02
DK2552910T3 (en) 2015-04-07
US9079881B2 (en) 2015-07-14
WO2011121308A1 (en) 2011-10-06
MX2012011382A (es) 2013-01-29
PL2552910T3 (pl) 2015-07-31
JP2013523706A (ja) 2013-06-17
ES2538085T3 (es) 2015-06-17
PT2552910E (pt) 2015-05-13
CN102918038A (zh) 2013-02-06
EP2552910B1 (en) 2015-03-11
HUE026442T2 (en) 2016-06-28
GB201005623D0 (en) 2010-05-19
CN102918038B (zh) 2015-09-09
JP5802737B2 (ja) 2015-11-04

Similar Documents

Publication Publication Date Title
ME02102B (me) Novi polimorf
GB2595776B (en) Therapeutic solid dosage forms
GB202008303D0 (en) Therapeutic compositions
NZ603043A (en) Pharmaceutical compositions comprising cftr modulators and administrations thereof
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
IL235761A0 (en) Process for preparing n - [5 - (3, 5 - difluoro - benzyl) -1h - indazole - 3 - yl] - 4 - (4 - methyl - piperazine - 1 - yl) - 2 - (tetrahydro - pyran - 4 - ylamino ) – benzamide
MX2012012571A (es) Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas.
ME02805B (me) Inhibitori cdc7
HRP20192132T1 (hr) Antagonist nk-1/nk-3 receptora za liječenje valunga
NZ603789A (en) Heteroaryl compounds and methods of use thereof
JP2017514910A5 (enExample)
JP2014507446A5 (enExample)
JP2014162794A5 (enExample)
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
IL214036A (en) Methods for determining the exact amount of particles in the inhaled preparation
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
JP2013507408A5 (enExample)
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
GEP20207098B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
NZ702239A (en) Heteroaryl compounds and methods of use thereof